Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmacology and Therapeutics

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2017.05.009PMID 28549597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• STAT5A‐mediated NOX5‐L expression promotes the proliferation and metastasis of breast cancer cells

  2017cited by this paper
• Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells

  2017cited by this paper
• A rare castration‐resistant progenitor cell population is highly enriched in Pten‐null prostate tumours

  2017cited by this paper
• Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells

  2017cited by this paper
• Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

  2016cited by this paper
• Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells

  2016cited by this paper
• Prolactin-induced PAK1 tyrosyl phosphorylation promotes FAK dephosphorylation, breast cancer cell motility, invasion and metastasis

  2016cited by this paper
• Identification of NEK3 Kinase Threonine 165 as a Novel Regulatory Phosphorylation Site That Modulates Focal Adhesion Remodeling Necessary for Breast Cancer Cell Migration*

  2016cited by this paper
• Stem Cell Antigen‐1 Identifies a Distinct Androgen‐Independent Murine Prostatic Luminal Cell Lineage with Bipotent Potential

  2016cited by this paper
• A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.

  2016cited by this paper
• Prolactin Signaling Stimulates Invasion via Na(+)/H(+) Exchanger NHE1 in T47D Human Breast Cancer Cells.

  2016cited by this paper
• Prolactin receptor in breast cancer: marker for metastatic risk.

  2016cited by this paper
• The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.

  2016cited by this paper
• STAT5A is regulated by DNA damage via the tumor suppressor p53.

  2016cited by this paper
• Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy

  2016cited by this paper
• Prolactin signaling through focal adhesion complexes is amplified by stiff extracellular matrices in breast cancer cells

  2016cited by this paper
• Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk.

  2016cited by this paper
• Plasma prolactin and breast cancer risk: a meta- analysis

  2016cited by this paper
• The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.

  2016cited by this paper
• Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer

  2016cited by this paper
• Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas.

  2016cited by this paper
• Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.

  2016cited by this paper
• Emerging Therapeutic Options for HER2-Positive Breast Cancer.

  2016cited by this paper
• A combined computational and structural model of the full-length human prolactin receptor

  2016cited by this paper
• ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling

  2016cited by this paper
• Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer

  2016cited by this paper
• Human and murine prostate basal/stem cells are not direct targets of prolactin.

  2015cited by this paper
• The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications

  2015cited by this paper
• Prolactin-induced prostate tumorigenesis.

  2015cited by this paper
• Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.

  2015cited by this paper
• Role of SRC family kinases in prolactin signaling.

  2015cited by this paper
• Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia

  2015cited by this paper
• The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts

  2015cited by this paper
• The many faces of prolactin in breast cancer.

  2015cited by this paper
• A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice.

  2015cited by this paper
• Minireview: prolactin regulation of adult stem cells.

  2015cited by this paper
• A Residue Quartet in the Extracellular Domain of the Prolactin Receptor Selectively Controls Mitogen-activated Protein Kinase Signaling*

  2015cited by this paper
• Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

  2015cited by this paper
• Residue 146 regulates prolactin receptor folding, basal activity and ligand-responsiveness: potential implications in breast tumorigenesis.

  2015cited by this paper
• Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

  2015cited by this paper
• Tyrosyl phosphorylated serine-threonine kinase PAK1 is a novel regulator of prolactin-dependent breast cancer cell motility and invasion.

  2015cited by this paper
• Prolactin Promotes Breast Cancer Cell Migration through Actin Cytoskeleton Remodeling

  2015cited by this paper
• Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study

  2015cited by this paper
• A basal stem cell signature identifies aggressive prostate cancer phenotypes

  2015cited by this paper
• Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

  2015cited by this paper
• Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer.

  2015cited by this paper
• Dense Collagen-I Matrices Enhance Pro-Tumorigenic Estrogen-Prolactin Crosstalk in MCF-7 and T47D Breast Cancer Cells

  2015cited by this paper
• Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014cited by this paper
• Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

  2014cited by this paper
• Amplified luminal progenitors in prostates of prolactin-transgenic mice

  2014cited by this paper
• Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions.

  2014cited by this paper
• Pharmacologic Suppression of JAK1/2 by JAK1/2 Inhibitor AZD1480 Potently Inhibits IL-6–Induced Experimental Prostate Cancer Metastases Formation

  2014cited by this paper
• Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort.

  2014cited by this paper
• Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor

  2014cited by this paper
• Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas

  2014cited by this paper
• Prolactin-induced prostate tumorigenesis links sustained Stat5 signaling with the amplification of basal/stem cells and emergence of putative luminal progenitors.

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Carboxypeptidase‐D is elevated in prostate cancer and its anti‐apoptotic activity is abolished by combined androgen and prolactin receptor targeting

  2014cited by this paper
• Luminal cells are favored as the cell of origin for prostate cancer.

  2014cited by this paper
• Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

  2014cited by this paper
• Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer

  2013cited by this paper
• A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development.

  2013cited by this paper
• Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell of origin model for prostate cancer heterogeneity

  2013cited by this paper
• Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer

  2013cited by this paper
• Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.

  2013cited by this paper
• STAT5A/B gene locus undergoes amplification during human prostate cancer progression.

  2013cited by this paper
• Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression

  2013cited by this paper
• Use of Prolactin Receptor Antagonist to Better Understand Prolactin Regulation of Pituitary Homeostasis

  2013cited by this paper
• Molecular Pathways Molecular Pathways : Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer

  2013cited by this paper
• Pharmacologic Inhibition of Jak2–Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer

  2013cited by this paper
• Stiff Collagen Matrices Increase Tumorigenic Prolactin Signaling in Breast Cancer Cells*

  2013cited by this paper
• The Inhibition of Stat5 by a Peptide Aptamer Ligand Specific for the DNA Binding Domain Prevents Target Gene Transactivation and the Growth of Breast and Prostate Tumor Cells

  2013cited by this paper
• Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.

  2013cited by this paper
• Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin

  2013cited by this paper
• Does the microenvironment influence the cell types of origin for prostate cancer?

  2013cited by this paper
• A Preclinical Xenograft Model Identifies Castration-Tolerant Cancer-Repopulating Cells in Localized Prostate Tumors

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• The WSXWS motif in cytokine receptors is a molecular switch involved in receptor activation: insight from structures of the prolactin receptor.

  2012cited by this paper
• Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways.

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Interplay between progesterone and prolactin in mammary development and implications for breast cancer.

  2012cited by this paper
• Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways

  2012cited by this paper
• Testosterone and prolactin increase carboxypeptidase‐D and nitric oxide levels to promote survival of prostate cancer cells

  2012cited by this paper
• Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

  2012cited by this paper
• Molecular mechanisms of prolactin and its receptor.

  2012cited by this paper
• JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.

  2012cited by this paper
• Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer

  2012cited by this paper
• Investigation of Prolactin Receptor Activation and Blockade Using Time-Resolved Fluorescence Resonance Energy Transfer

  2011cited by this paper
• Placental hormones and the control of maternal metabolism and fetal growth

  2011cited by this paper
• Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer.

  2011cited by this paper
• Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.

  2011cited by this paper
• Discovery of the improved antagonistic prolactin variants by library screening.

  2011cited by this paper
• Lactogens and estrogens in breast cancer chemoresistance

  2011cited by this paper
• Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland

  2011cited by this paper
• Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo

  2011cited by this paper
• The role of Stat5 transcription factors as tumor suppressors or oncogenes.

  2011cited by this paper
• Amplification of the prolactin receptor gene in mammary lobular neoplasia

  2011cited by this paper

• Osthole suppresses prostate cancer progression by modulating PRLR and the JAK2/STAT3 signaling axis

  2025cites this paper
• From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections

  2025cites this paper
• A role for JAK2 in mediating cell surface GHR-PRLR interaction

  2024cites this paper
• Growth Hormone Action as a Target in Cancer: Significance, Mechanisms and Possible Therapies.

  2024cites this paper
• Prolactin-specific induction of the nuclear translocation of porcine prolactin receptor in porcine mammary epithelial cells.

  2024cites this paper
• The genomic basis of childhood T-lineage acute lymphoblastic leukaemia

  2024cites this paper
• PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling

  2024cites this paper
• Current Insights in Prolactin Signaling and Ovulatory Function

  2024influential citation
• Prolactin regulates RANKL expression via signal transducer and activator of transcription 5a signaling in mammary epithelial cells of dairy cows

  2023cites this paper
• Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview

  2023cites this paper
• Andrological aspects of prolactin secretion disorders

  2023cites this paper
• Structure and function of a dual antagonist of the human growth hormone and prolactin receptors with site-specific PEG conjugates

  2023cites this paper
• The High Level of RANKL Improves IκB/p65/Cyclin D1 Expression and Decreases p-Stat5 Expression in Firm Udder of Dairy Goats

  2023cites this paper
• Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?

  2023cites this paper
• Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: the case for longer breastfeeding.

  2022cites this paper
• Preparation of Super-Active Prolactin Receptor Antagonists.

  2022cites this paper
• Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness

  2022cites this paper
• Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer

  2022cites this paper
• Novel neoplasms associated with syndromic pediatric medulloblastoma: integrated pathway delineation for personalized therapy

  2022cites this paper
• Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer

  2022cites this paper
• Bromocriptine therapy: Review of mechanism of action, safety and tolerability

  2022cites this paper
• Serum hormone levels and normal breast histology among premenopausal women

  2022cites this paper
• Electronic, spectroscopic, molecular docking and molecular dynamics studies of neutral and zwitterionic forms of 3, 4-dihydroxy-L-phenylalanine: A novel lung cancer drug

  2022cites this paper
• The brain as a source and a target of prolactin in mammals

  2022cites this paper
• Molecular Evolutionary Insights from PRLR in Mammals.

  2021cites this paper
• Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues

  2021cites this paper
• Decoding signaling pathways involved in prolactin-induced neuroprotection: a review.

  2021cites this paper
• Periplasmic synthesis and purification of the human prolactin antagonist Δ1-11-G129R-hPRL

  2021cites this paper
• PCLasso: a protein complex-based, group lasso-Cox model for accurate prognosis and risk protein complex discovery

  2021cites this paper
• Morphological and molecular effects of overexpressed GH on mice mammary gland.

  2021cites this paper
• THE ROLE OF PROLACTIN RECEPTOR SIGNALING IN LIVER HOMEOSTASIS AND DISEASE

  2021cites this paper
• Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

  2021cites this paper
• The Potential Prognostic and Therapeutic Implications of Prolactin Receptor and Growth Hormone-releasing Hormone Receptor Expression in Uterine Leiomyosarcomas

  2021cites this paper
• Expression of long-form prolactin receptor is associated with lower disease-free and overall survival in node-negative breast cancer patients.

  2020cites this paper
• The role of the prolactin receptor pathway in the pathogenesis of glioblastoma: what do we know so far?

  2020cites this paper
• Neuroendocrine carcinoma of the breast with hyperprolactinemia: report of two cases and a minireview.

  2020cites this paper
• Discovery of regulatory noncoding variants in individual cancer genomes by using cis-X

  2020cites this paper
• Generation of a lentiviral vector system to efficiently express bioactive recombinant human prolactin hormones.

  2020cites this paper
• Prolactin and androgen R1881 induce pro-survival carboxypeptidase-D and EDD E3 ligase in triple-negative and HER2+ breast cancer.

  2020cites this paper
• Vaccarin promotes proliferation of and milk synthesis in bovine mammary epithelial cells through the Prl receptor-PI3K signaling pathway.

  2020cites this paper
• A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer

  2020cites this paper
• Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer: overview and therapeutic opportunities

  2020cites this paper
• Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

  2020cites this paper
• Human Pathway-Based Disease Network

  2019cites this paper
• Identifying Cancer-Related Signaling Pathways Using Formal Methods

  2019cites this paper
• Expansion of chemical space based on a pyrrolo[1,2-a]pyrazine core: Synthesis and its anticancer activity in prostate cancer and breast cancer cells.

  2019cites this paper
• Prolactin and its receptor as therapeutic targets in glioblastoma multiforme

  2019cites this paper
• Hyperprolactinaemia

  2019cites this paper
• In silico identification of natural products with anticancer activity using a chemo-structural database of Brazilian biodiversity

  2019cites this paper
• STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice

  2019cites this paper
• Identification and validation of microRNAs that synergize with miR-34a – a basis for combinatorial microRNA therapeutics

  2019cites this paper
• Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease

  2019cites this paper
• A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Why and How?

  2019cites this paper
• Seasonal expressions of prolactin, prolactin receptor and STAT5 in the scented glands of the male muskrats (Ondatra zibethicus)

  2019cites this paper
• Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis.

  2019cites this paper
• Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.

  2018cites this paper
• The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis

  2018influential citation
• Testosterone, prolactin, and oncogenic regulation of the prostate gland. A new concept: Testosterone-independent malignancy is the development of prolactin-dependent malignancy!

  2018cites this paper
• ATM Is Required for the Prolactin-Induced HSP90-Mediated Increase in Cellular Viability and Clonogenic Growth After DNA Damage

  2018cites this paper
• Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer

  2018cites this paper
• Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification

  2015cites this paper